CMS modified NCD 166 — the Hepatitis Panel / Acute Hepatitis Panel national coverage determination — effective March 7, 2026. Here's what billing teams need to do.
The Centers for Medicare & Medicaid Services updated NCD 166, which governs Medicare coverage of the acute hepatitis panel: Hepatitis A antibody IgM (HAAb-IgM), Hepatitis B core antibody IgM (HBcAb-IgM), Hepatitis B surface antigen (HBsAg), and Hepatitis C antibody. This policy applies broadly to diagnostic laboratory billing under Medicare and affects any practice, lab, or hospital outpatient department ordering these tests. The policy does not list specific CPT or HCPCS codes in this version — but that doesn't reduce your exposure if your team is billing hepatitis panel workups for Medicare patients.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Hepatitis Panel / Acute Hepatitis Panel |
| Policy Code | NCD 166 |
| Change Type | Modified |
| Effective Date | 2026-03-07 |
| Impact Level | Medium |
| Specialties Affected | Clinical laboratory, gastroenterology, infectious disease, internal medicine, emergency medicine, hepatology, family medicine |
| Key Action | Review your hepatitis panel ordering documentation and medical necessity criteria against NCD 166 before March 7, 2026 |
CMS Hepatitis Panel Coverage Criteria and Medical Necessity Requirements 2026
NCD 166 covers the acute hepatitis panel as a diagnostic laboratory test under Medicare. The panel is specifically composed of four components: Hepatitis A antibody IgM (HAAb-IgM), Hepatitis B core antibody IgM (HBcAb-IgM), Hepatitis B surface antigen (HBsAg), and Hepatitis C antibody. That's it. Tests outside this four-component set are not part of this panel under the NCD.
Medical necessity is the controlling issue here, as it is with every diagnostic panel under Medicare. CMS's coverage policy for this panel rests on the clinical presentation of acute hepatitis — meaning your documentation needs to support that the ordering physician had a clinical reason to suspect viral hepatitis from HAV, HBV, or HCV. A vague order or a reflex protocol without supporting documentation is a claim denial waiting to happen.
The policy recognizes that HBsAg is an early marker, appearing four to eight weeks after HBV exposure and typically clearing within six months. HBcAb-IgM becomes detectable two to three months post-exposure. CMS's own clinical rationale acknowledges that a negative HBsAg does not exclude HBV — which is why the panel includes HBcAb-IgM as a complementary marker. Your documentation should reflect this clinical logic when ordering the full panel rather than individual components.
HCV antibody is included as the fourth panel component. CMS notes that HCV is the most common cause of post-transfusion hepatitis. If a clinician is ordering HCV antibody in isolation for screening purposes — not as part of an acute hepatitis workup — that falls outside this panel's medical necessity framework. Prior authorization is not explicitly required under NCD 166, but medical necessity documentation is not optional. Missing or thin documentation remains one of the top drivers of claim denial on diagnostic panels.
The reimbursement question that often comes up: billing the panel as a bundled service versus billing components separately. NCD 166 defines the panel as a discrete unit. Unbundling the four components into separate claims when the clinical scenario supports the full panel is a compliance risk under NCCI edits and Medicare billing guidelines. Check your charge capture configuration against this before March 7, 2026.
CMS Hepatitis Panel Exclusions and Non-Covered Indications
NCD 166 is not an open-ended authorization for all hepatitis-related testing. Several related tests are explicitly outside the scope of this panel, and billing them as part of an acute hepatitis panel workup is incorrect.
Hepatitis B e antigen (HBeAg) and Hepatitis B e antibody (HBeAb) — the envelope antigen and antibody — are not included in NCD 166. CMS acknowledges their clinical relevance for assessing HBV infectivity, but they are separate tests. If your providers are routinely adding HBeAg and HBeAb to an acute hepatitis workup and your billing team is bundling those into the panel claim, you have a billing problem that needs to be corrected before March 7, 2026.
IgG anti-HAV, while clinically useful for confirming prior immunity or past infection, is also not part of this panel. NCD 166 covers IgM anti-HAV only — the acute infection marker. Ordering IgG anti-HAV for surveillance or immunity documentation is a separate clinical scenario that requires separate medical necessity support.
HBsAb (Hepatitis B surface antibody) monitoring after vaccination — while addressed in the NCD's clinical narrative — is a distinct use case. CMS notes that HBsAb alone may be used monthly for up to six months post-vaccination series to verify adequate antibody response. This is not the acute hepatitis panel. Billing it as such is incorrect.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Acute HAV infection workup (IgM anti-HAV) | Covered | Not specified in policy | Medical necessity documentation required; IgM appears within ~4 weeks of exposure |
| Acute HBV infection workup (HBcAb-IgM + HBsAg) | Covered | Not specified in policy | Both markers required for best diagnostic accuracy per CMS clinical rationale |
| Acute HCV exposure workup (HCV antibody) | Covered | Not specified in policy | Most common post-transfusion hepatitis; part of the four-component panel |
| HBV infectivity assessment (HBeAg / HBeAb) | Not Covered under NCD 166 | Not specified in policy | Separate tests outside this panel's scope; bill separately with independent medical necessity |
| IgG anti-HAV (prior immunity or past infection) | Not Covered under NCD 166 | Not specified in policy | Distinct from IgM; not part of the acute panel |
| HBsAb monitoring post-vaccination | Not Covered under NCD 166 | Not specified in policy | Separate use case; monthly monitoring up to 6 months post-vaccination series; requires independent documentation |
| Chronic HBV monitoring (HBsAg + HBcAb-IgG) | Not Covered under NCD 166 | Not specified in policy | Chronic disease management is a separate clinical scenario from the acute panel |
CMS Hepatitis Panel Billing Guidelines and Action Items 2026
| # | Action Item |
|---|---|
| 1 | Audit your hepatitis panel order sets before March 7, 2026. Pull a sample of recent claims that included HBcAb-IgM, HBsAg, HAAb-IgM, and HCV antibody together. Confirm your charge capture is treating the four-component acute hepatitis panel as a bundled unit — not as four separately ordered and separately billed components. |
| 2 | Verify that HBeAg, HBeAb, and IgG anti-HAV are not being bundled into your hepatitis panel claims. These are outside NCD 166's scope. If your EHR order sets or lab panels automatically include them alongside the four covered components, your billing team needs to know — and your ordering workflow may need to be adjusted. |
| 3 | Review your medical necessity documentation standards for acute hepatitis panel orders. The CMS coverage policy for NCD 166 is clinically grounded — it expects the ordering physician to have a clinical reason to suspect HAV, HBV, or HCV in an acute presentation. "Rule out hepatitis" without supporting clinical context is not sufficient. Talk to your medical director about documentation standards if your team hasn't formalized these. |
| 4 | Train your billing team on the distinction between the acute hepatitis panel and post-vaccination HBsAb monitoring. These are two different clinical scenarios. HBsAb-only monitoring for up to six months after a completed HBV vaccination series is a legitimate clinical use case — but it is not the acute panel. Billing it as the full panel is incorrect. The reimbursement profile is different, and the claim denial risk is real. |
| 5 | Check for NCCI edits and LCD overlap. NCD 166 is a national coverage determination, but your local MAC may have an LCD that adds additional coverage criteria or documentation requirements on top of the NCD. If you bill hepatitis panels with any frequency, confirm your MAC's current LCD position and reconcile it with NCD 166 before the March 7, 2026 effective date. If you're uncertain how the overlap applies to your payer mix, loop in your compliance officer before the effective date. |
| 6 | Document the clinical timeline in acute hepatitis workups. The CMS policy is explicit that the timing of marker appearance matters clinically — HBsAg appears four to eight weeks post-exposure, HBcAb-IgM two to three months post-exposure. If a provider orders the full panel very early in a suspected exposure window, the documentation should reflect why all four components were ordered at that point. Auditors notice when the clinical timeline and the order pattern don't align. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Hepatitis Panel / Acute Hepatitis Panel Under NCD 166
The policy data for NCD 166 (policy key 166-v1) does not list specific CPT, HCPCS, or ICD-10 codes in this version. This is worth flagging directly: the absence of code-level detail in the NCD itself means your billing team needs to cross-reference the applicable CPT codes (typically found under the hepatitis antibody and antigen testing code range) against your MAC's LCD and any bundling edits in your claim scrubber.
The four clinical components covered by this panel — HAAb-IgM, HBcAb-IgM, HBsAg, and HCV antibody — each have corresponding CPT codes for individual component billing. Whether those are billed under a panel code or individually depends on NCCI edits, MAC guidance, and your EHR/lab billing configuration. This is exactly the situation where "no codes listed in the NCD" creates billing risk: teams assume they're fine, then get denied because the panel-versus-component logic wasn't resolved.
Check the full policy at the source — NCD 166 on PayerPolicy — and pull your MAC's current LCD alongside it. Don't rely on this NCD alone to build your charge capture logic.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.